27-08-2019
Pavel Kapysh / Shutterstock.com
Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Celgene, Amgen, psoriasis, apremilast, otezla, arthritis, acquisition, patent, biosimilar, biologic, inflammation, disease
